IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation Final Settlement Requires Court Approval

IsoRay, Inc. Enters Into Agreement to

Settle Class Action Shareholder Litigation

Final Settlement Requires Court Approval

RICHLAND, Wash., September 27, 2016 -

- IsoRay, Inc. ("IsoRay") (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and

medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, today

announced that on September 23, 2016, it entered into a Stipulation of Settlement (the "Settlement"), pursuant to

which IsoRay and IsoRay's former CEO (together, the "Defendants") have, subject to certain conditions and

approvals, agreed to settle the previously-disclosed consolidated securities class action litigation, In re IsoRay, Inc.

Securities Litigation, Case No. 4:15-cv-05046-LRS (the "Litigation"), pending in the U.S. District Court for

the Eastern District of Washington.

If the Settlement becomes final, among

other things, (i) the claims against the Defendants will be dismissed with prejudice and released, such that every member

of the settlement class will be barred from asserting against the Defendants any claims alleged in the complaint or arising from

the complaint, and (ii) a payment of $3,537,500 will be made for the benefit of the settlement class, which IsoRay expects

to be funded entirely by its insurance carriers. The Defendants have denied and continue to deny each and all of the claims alleged

by the plaintiffs in the Litigation. Nevertheless, the Defendants have agreed to the Settlement to eliminate the uncertainty, distraction,

burden, and expense of further litigation.

The proposed Settlement is subject to a

number of conditions, including, among other items, preliminary and final court approval. Details regarding any proposed Settlement

will be communicated to potential class members prior to the final court approval. At this time, there can be no assurance that

the conditions to effect the Settlement will be met or that the settlement of the Litigation will receive the required court approvals.

IsoRay, Inc., through its subsidiary, IsoRay

Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the

body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting

Safe Harbor Statement

This press release contains "forward-looking"

statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, regarding

the prospective resolution of the Litigation. Such forward-looking statements are based on current expectations, are predictive

in nature, and involve known and unknown risks and uncertainties that may cause IsoRay's actual outcomes and results to differ

materially from those projected or contemplated in the forward-looking statements. These risks and uncertainties include, but are

not limited to, the risk that the Litigation Settlement will not be finalized or approved by the court or that other conditions

may not be met for approval. If the Settlement is not finalized, the ultimate resolution and the impact on IsoRay cannot be assessed.

Whether or not the Settlement is approved depends on various factors, including, but not limited to, the number of and reasons

for any potential objections to the Settlement or the number of class members excluding themselves from the Litigation Settlement.

IsoRay can give no assurances that any results or events projected or contemplated by its forward-looking statements will in fact

occur and IsoRay cautions you not to place undue reliance on these statements. Unless required to do so by law, IsoRay undertakes

no duty to update these forward-looking statements to reflect any future events, developments or otherwise.

Stephanie Prince, Managing Director